Clinical Trial Platform Articles & Analysis
34 news found
The latest round will support legal and consulting costs as well as continued expansion of its research, team, infrastructure, data acquisition and business development. 4D Path’s patented precision oncology platform unveils previously hidden data to instantly provide biomarker profiling and stratification directly from a single H&E biopsy image. By eliminating the ...
The two new business units will use Cellworks’ biosimulation platform and Computational Biology Model (CBM) to predict responses to pharmaceutical interventions in silico, thereby streamlining the clinical trial process by identifying the right patients more rapidly, which in turn reduces the time and expense of developing successful ...
Business Update Highlights “Our Q2 results demonstrate BioMark’s continued efforts to advance our technology platform with exceptional clinical data, expand our global partnerships, and accelerating the commercialization of its early lung cancer blood-based assay despite a challenging macro environment” said CEO Rashid Bux. ...
Exclusive global license for CORE NK platform (CHM 0201) executed with Case Western Reserve University in Ohio Initial Phase 1 clinical trial results of the CORE NK platform (CHM 0201) were published demonstrating safety and encouraging activity in blood cancers and solid tumours One patient achieved a complete response that ...
Endpoint Clinical, the leader in global interactive response technology (IRT®) for clinical trials, and Egnyte, the secure platform for content collaboration and governance, today announced that Endpoint Clinical has partnered with Egnyte, providing a Google Cloud-compliant platform to ...
Dr Steven Chance, CEO, Oxford Brain Diagnostics said ‘we are very proud to be partnering with INmune Bio on this phase 2 AD clinical trial using CDM® as a secondary outcome measure. Alzheimer’s remains a complex condition and our involvement in this trial means that monitoring the interaction between the cortical microstructure ...
BioMark is currently pursuing two clinical trials using this liquid biopsy platform that can improve identification and assessing response to treatment for patients with lung cancer and glioblastoma. “Receiving this critical patent in the US completes our global registration of this family of patents as we continue to invest in enhancing ...
Immediate applications of Lifespin’s commercial services, which leverages access to Lifespin’s proprietary software and database, include quality control for synthetic/natural compounds, quantitative profiling of metabolites in liquid samples, monitoring of drug responses and organ-specific metabolic phenotyping, and precision nutrition to therapeutic drug monitoring and longitudinal ...
xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG). ...
ByxCures
By using Biobeat’s medical-grade wearables we are able to enhance clinical trials with vital signs collection to generate real-world evidence remotely and conveniently from the patient’s home. Our platform supports decentralized clinical trials and significantly reduces the logistics burden and the ...
We look forward to continued progress from the Senti Bio team including advancing product candidates towards and into clinical trials, solidifying its clinical-scale cGMP manufacturing capabilities, and expanding its gene circuit offerings across multiple diseases and modalities via partnering ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The ...
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces the appointment of Tim Obara, a highly experienced commercial healthcare executive, as Vice President Business Development. ...
Sallés joins the Kallyope senior leadership team as the company advances its pioneering drug discovery platform, clinical trials, and pipeline of multiple programs modulating gut-brain axis signaling across a broad range of therapeutic areas. ...
ViGeneron’s vgAAV vector platform is designed to overcome the limitations of existing adeno-associated virus (AAV)-based gene therapies. ...
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the appointments of George Shiebler as General Counsel and Anita Kawatra as Executive Vice President, Corporate Affairs, to help steer the company as it advances its pioneering drug discovery platform, clinical ...
Embedding this AI technology within PathPresenter’s emerging ClinPx platform – a scanner-agnostic digital pathology workflow solution – could accelerate the adoption of AI tools within clinical workflows. ...
In 2019, the companies entered into a strategic clinical trial collaboration agreement and an equity investment agreement to develop novel personalized neoantigen cancer vaccines. ...
The funds will be used to advance the company’s pioneering drug discovery platform, clinical trials, and pipeline of multiple programs across a broad range of therapeutic areas. ...
About the Transpose® RT System and FDA approved clinical trials InGeneron’s Transpose® RT cell therapy platform consists of a processing unit, a set of disposables and Matrase®, a proprietary enzyme mixture. ...